Extreme variability in the formation of chlorpyrifos oxon (CPO) in patients poisoned by chlorpyrifos (CPF)

Biochemical Pharmacology

Volumn 78, Issue 5, 2009, Pages 531-537

  Eyer, Florian ^a   Roberts, Darren M ^b   Buckley, Nicholas A ^c   Eddleston, Michael ^d   Thiermann, Horst ^e   Worek, Franz ^e   Eyer, Peter ^f  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Burns   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d Scottish Poisons Information Bureau   (United Kingdom)

^e BUNDESWEHR INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (Germany)

^f UNIVERSITY OF MUNICH   (Germany)

Author keywords

Chlorpyrifos; Organophosphorus; Poisoning; Pralidoxime; Toxicokinetics

Indexed keywords

ACETYLCHOLINESTERASE; ACTIVATED CARBON; CHLORPYRIFOS; CHLORPYRIFOS EXON; ORGANOPHOSPHATE INSECTICIDE; PRALIDOXIME; UNCLASSIFIED DRUG;

ARTICLE; BLOOD LEVEL; CHLORPYRIFOS BLOOD LEVEL; CHLORPYRIFOS INTOXICATION; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; HUMAN; INCUBATION TIME; INTOXICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; TREATMENT DURATION;

CHLORPYRIFOS; CHROMATOGRAPHY, GAS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; INSECTICIDES; MASS SPECTROMETRY;

EID: 67649499827     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.05.004     Document Type: Article

References (34)

1. Gunnell D., Eddleston M., Phillips M.R., and Konradsen F. The global distribution of fatal pesticide self-poisoning: systematic review. BMC Public Health 7 (2007) 357
2. Eddleston M., Eyer P., Worek F., Mohamed F., Senarathna L., von Meyer L., et al. Differences between organophosphorus insecticides in human self-poisoning: a prospective cohort study. Lancet 366 (2005) 1452-1459
3. Sams C., Cocker J., and Lennard M.S. Biotransformation of chlorpyrifos and diazinon by human liver microsomes and recombinant human cytochrome P450s (CYP). Xenobiotica 34 (2004) 861-873
4. Foxenberg R.J., McGarrigle B.P., Knaak J.B., Kostyniak P.J., and Olson J.R. Human hepatic cytochrome P-450-specific metabolism of parathion and chlorpyrifos. Drug Metab Dispos 35 (2007) 189-193
5. Buratti F.M., Volpe M.T., Meneguz A., Vittozzi L., and Testai E. CYP-specific bioactivation of four organophosphorothioate pesticides by human liver microsomes. Toxicol Appl Pharmacol 186 (2003) 143-154
6. Fujioka K., and Casida J.E. Glutathione S-transferase conjugation of organophosphorus pesticides yields S-phospho-, S-aryl-, and S-alkylglutathione derivatives. Chem Res Toxicol 20 (2007) 1211-1217
7. Choi K., Joo H., Rose R.L., and Hodgson E. Metabolism of chlorpyrifos and chlorpyrifos oxon by human hepatocytes. J Biochem Mol Toxicol 20 (2006) 279-291
8. Mutch E., Daly A.K., and Williams F.M. The relationship between PON1 phenotype and PON1-192 genotype in detoxification of three oxons by human liver. Drug Metab Dispos 35 (2007) 315-320
9. Heilmair R., Eyer F., and Eyer P. Enzyme-based assay for quantification of chlorpyrifos oxon in human plasma. Toxicol Lett 181 (2008) 19-24
10. Drevenkar V., Vasilic Z., Stengl B., Frobe Z., and Rumenjak V. Chlorpyrifos metabolites in serum and urine of poisoned persons. Chem Biol Interact 87 (1993) 315-322
11. Timchalk C., Nolan R.J., Mendrala A.L., Dittenber D.A., Brzak K.A., and Mattsson J.L. A Physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model for the organophosphate insecticide chlorpyrifos in rats and humans. Toxicol Sci 66 (2002) 34-53
12. Amitai G., Moorad D., Adani R., and Doctor B.P. Inhibition of acetylcholinesterase and butyrylcholinesterase by chlorpyrifos-oxon. Biochem Pharmacol 56 (1998) 293-299
13. Jayawardane P., Dawson A.H., Weerasinghe V., Karalliedde L., Buckley N.A., and Senanayake N. The spectrum of intermediate syndrome following acute organophosphate poisoning: a prospective cohort study from Sri Lanka. PLoS Med 5 (2008) 1143-1153
14. Eddleston M., Juszczak E., Buckley N.A., Senarathna L., Mohamed F., Dissanayake W., et al. Multiple-dose activated charcoal in acute self-poisoning: a randomised controlled trial. Lancet 371 (2008) 579-587
15. Eddleston M., Buckley N.A., Eyer P., and Dawson A.H. Management of acute organophosphorus pesticide poisoning. Lancet 371 (2008) 597-607
16. Worek F., Mast U., Kiderlen D., Diepold C., and Eyer P. Improved determination of acetylcholinesterase activity in human whole blood. Clin Chim Acta 288 (1999) 73-90
17. Thiermann H., Mast U., Klimmek R., Eyer P., Hibler A., Pfab R., et al. Cholinesterase status, pharmacokinetics and laboratory findings during obidoxime therapy in organophosphate poisoned patients. Hum Exp Toxicol 16 (1997) 473-480
18. Eyer P. The role of oximes in the management of organophosphorus pesticide poisoning. Toxicol Rev 22 (2003) 165-190
19. Worek F., Bäcker M., Thiermann H., Szinicz L., Mast U., Klimmek R., et al. Reappraisal of indications and limitations of oxime therapy in organophosphate poisoning. Hum Exp Toxicol 16 (1997) 466-472
20. Worek F., Eyer P., and Szinicz. Inhibition, reactivation, and aging kinetics of cyclohexylmethylphosphonofluoridate-inhibited human cholinesterases. Arch Toxicol 72 (1998) 580-587
21. Stenzel J., Worek F., and Eyer P. Preparation and characterization of dialkylphosphoryl-obidoxime conjugates, potent anticholinesterase derivatives that are quickly hydrolyzed by human paraoxonase (PON1(192Q)). Biochem Pharmacol 74 (2007) 1390-1400
22. Li W.-F., Costa L.G., Richter R.J., Hagen T., Shih D.M., Tward A., et al. Catalytic efficiency determines the in vivo efficacy of PON 1 for detoxifying organophosphorus compounds. Pharmacogenetics 10 (2000) 767-779
23. Kuo C.-L., and La Du B.N. Calcium binding by human and rabbit serum paraoxonases. Structural stability and enzymatic activity. Am Soc Pharmacol Exp Ther 26 (1998) 653-660
24. Schopfer L.M., Voelker T., Bartels C.F., Thompson C.M., and Lockridge O. Reaction kinetics of biotinylated organophosphorus toxicant, FP-biotin, with human acetylcholinesterase and human butyrylcholinesterase. Chem Res Toxicol 18 (2005) 747-754
25. Aurbek N., Thiermann H., Eyer F., Eyer P., and Worek F. Suitability of human butyrylcholinesterase as therapeutic marker and pseudo catalytic scavenger in organophosphate poisoning: a kinetic analysis. Toxicology 259 (2009) 133-139
26. Kiderlen D., Worek F., Klimmek R., and Eyer P. The phosphoryl oxime-destroying activity of human plasma. Arch Toxicol 74 (2000) 27-32
27. Sultatos L.G., Basker K.M., Shao M., and Murphy S.D. The interaction of the phosphorothioate insecticides chlorpyrifos and parathion and their oxygen analogues with bovine serum albumin. Mol Pharmacol 26 (1984) 99-104
28. Li B., Schopfer L., Hinrichs S.H., Masson P., and Lockridge O. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry assay for organophosphorus toxicants bound to human albumin at Tyr 411. Anal Biochem 361 (2007) 263-272
29. Peeples E.S., Schopfer L.M., Duysen E.G., Spaulding R., Voelker T., Thompson C.M., et al. Albumin, a new biomarker of organophosphorus toxicant exposure, identified by mass spectrometry. Toxicol Sci 83 (2005) 303-312
30. Li B., Sedlacek M., Manoharan I., Boopathy R., Duysen E.G., Masson P., et al. Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem Pharmacol 70 (2005) 1673-1684
31. Richter R.J., and Jarvik G.P. Furlong CE. Paraoxonase 1 (PON1) status and substrate hydrolysis. Toxicol Appl Pharmacol 235 (2009) 1-9
32. Chia S.E., Mohamed Ali S., Yap P.H., Gan L., Ong Y.B., and Chia K.S. Distribution of PON1 polymorphisms-PON1Q192R and PON1L55M among Chinese, Malay and Indian males in Singapore and possible susceptibility to organophosphate exposure. Neurotoxicology 30 (2009) 214-219
33. Wang H., and Tompkins L.M. CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr Drug Metab 9 (2008) 598-610
34. Ramachandran G., Ramesh K., Hemanth Kumar A.K., Jagan I., Vasantha M., Padmapriyadarsini C., et al. Association of high T allele frequency of CYP2B6 G516T polymorphism among ethnic south Indian HIV-infected patients with elevated plasma efavirenz and nevirapine. J Antimicrob Chemother 63 (2009) 841-843